April 5, 2022 News by Marta Figueiredo, PhD #AAN2022 ā Long-term Evobrutinib Safe, Effective in Relapsing MS Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of multiple sclerosis (MS), according to 2.5 years of data from a Phase 2 extension study. These findings ā supporting evobrutinibās therapeutic potential in relapsing MS ā were shared in an…
April 4, 2022 News by Lindsey Shapiro, PhD Irisin Hormone May Underlie Benefits of Aerobic Exercise for RRMS Six weeks of aerobic exercise led to benefits in cognition, fatigue, and depression among people with relapsing-remitting multiple sclerosis (RRMS), which may be due to increases in blood levels of a hormone called irisin, according to data from a randomized, controlled trial. “Considering the high prevalence of neuropsychiatric symptoms…
April 4, 2022 News by Margarida Maia, PhD COVID-19 Not Linked to Long-term Worsening of RRMS: Iranian Study COVID-19 does not seem to be linked to increased disability worsening or more relapses in the long term for people with relapsing-remitting multiple sclerosis (RRMS), an Iranian study suggests. The study was relatively small, the researchers noted, indicating that more research is needed in the future to determine the…
April 1, 2022 News by Lindsey Shapiro, PhD Use of GA Depot in Treating Progressive MS Given US Patent Mapi Pharma announced that it has been granted a U.S. patent covering the use of GA Depot, a potential long-acting formulation of glatiramer acetate, in people with progressive forms of multiple sclerosis (MS). The U.S. Patent and Trademark Office patent, No. 11,167,003, is titled, ā…
March 29, 2022 News by Hawken Miller Artist With MS Finds Beauty, Individuality in MRI Brain Scans Reviewing an MRI of oneās brain and seeing lesions on it is a frightening prospect for people with multiple sclerosis (MS). āThe lesions, the bright spots on a brain scan, that’s probably the last place in your body most of us want to see things. [It’s] such an important…
March 21, 2022 News by Lindsey Shapiro, PhD BDNF Risk Variant Linked to Brain Inflammation in New RRMS Patients A risk variant in the BDNF gene is tied to increased brain inflammation and reduced cortical thickness on MRI scans in people newly diagnosed with relapsing-remitting multiple sclerosis (RRMS), a recent study found. āWe report for the first time an association between the BDNF [genetic variant] and central inflammation…
March 18, 2022 News by Marisa Wexler, MS MS Doctors, Nurses in UK Struggle With Marking Transition to SPMS Among healthcare providers in the U.K., considerable variation exists in marking the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS), a study based on interview responses reports. Neurologists and nurses with MS specialties also expressed a reluctance to label patients as having progressed to…
March 16, 2022 News by Marisa Wexler, MS BCG Vaccine for TB Not Linked to MS Risk: Large Canadian Study Getting the Bacillus Calmette-Guerin (BCG) vaccine to protect against tuberculosis (TB) ā an immunization often given to infants and small children in countries where TB is common ā does not decrease a person’s risk of developing multiple sclerosis (MS), according to a new study. “Within a large birth cohort…
March 16, 2022 News by Marisa Wexler, MS Novantrone Lowers Relapses, Eases Disability in Highly Active RRMS Initial treatment with Novantrone (mitoxantrone) can reduce the risk of relapses and worsening disability in people with highly active relapsing-remitting multiple sclerosis (RRMS), according to a 10-year study from France. “Our results support the short-term use of [Novantrone], followed by a maintenance therapy for patients with early highly…
March 11, 2022 News by Marisa Wexler, MS Worsening Disability in Absence of Relapses ‘Underestimated’ in MS A substantial amount of disability worsening happens independently of relapses in people with multiple sclerosis (MS), including those in earlier stages of relapsing-remitting disease, a study in a large patient database reported. While its findings “confirm relapses contribute to the accumulation of disability, primarily early in multiple sclerosis,” data…
March 9, 2022 Columns by Beth Ullah Lyrics and Loving Myself: Rediscovering My Lost Voice āMost of the time, the greatest rewards come from doing the things that scare you the most. Maybe you’ll get everything you wish for. Maybe you’ll get more than you ever could have imagined. Who knows where life will take you? The road is long, and in the end, the…
March 9, 2022 News by Somi Igbene, PhD Ketogenic Diet Eases Symptoms, Aids Life Quality in Small RRMS Study A short-term ketogenic diet, which dramatically cuts carbohydrate consumption, is safe and results in significant improvements in people with relapsing-remitting multiple sclerosis (RRMS), a small study in patients reported. āOur study provides evidence that a ketogenic diet is safe and beneficial, reducing some symptoms for people with MS, when…
March 4, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā Blood NfL Levels May Help Quantify Relapse Severity Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL levels during periods of active inflammation predicted more [brain] atrophy,” researchers wrote in an abstract titled…
March 1, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā Cortical Lesions Seen to Predict Disability Worsening A higher burden of lesions in the brain’s cortex is associated with a greater likelihood of disability worsening in multiple sclerosis (MS) and transition to secondary progressive MS (SPMS), researchers report. These results suggest that “monitoring cortical lesion volume … could be useful when stratifying risk of disability…
March 1, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā Spinal Cord Atrophy Predicts ‘Silent Progression’ in Early MS A faster rate of atrophy in the spinal cord of people in earlier stages ofĀ multiple sclerosis (MS) is likely to indicate “silent progression” ā worsening disability in the absence of relapses ā and a swifter conversion to secondary progressive MS (SPMS), new data show. Antje Bischof, MD, with…
February 28, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā Iron Rim Lesions Linked to More Severe Disease Iron rim lesions, or specific regions of chronic inflammation seen on MRI scans of the brain, are associated with greater disability and poorer outcomes in multiple sclerosis (MS), a study indicates. These findings “could support the use of iron rim lesions as an imaging biomarker for disease severity and…
February 7, 2022 News by Hawken Miller Endurance Sports Inspire Young Frenchman With RRMS Sports was a huge part of Armand Thoinetās life, and when he was diagnosed with relapsing-remitting multiple sclerosis (MS) one week before his 19th birthday, that life turned upside down. He could no longer engage in activities that mattered greatly to him, such as rugby, tennis, and skiing. āI…
February 1, 2022 News by Marisa Wexler, MS Study: DNA Methylation in T-cells Affected by MS and Its Treatments Multiple sclerosis (MS) is characterized by changes in methylation ā a type of chemical modification in the DNA that changes how genes are read ā in immune cells called T-cells, according to a new study. The results also suggest that treatments for MS can help to normalize methylation…
January 26, 2022 News by Lindsey Shapiro, PhD After Pregnancy, Women Show More Brain Lesions, Volume Loss Women with relapsing-remitting multiple sclerosis (RRMS) have more brain lesions and accelerated brain volume loss (BVL) after pregnancy compared with pre-pregnancy measurements, recent data showed. Brain lesions in the early postpartum period ā the first months following childbirth āĀ were associated with a higher risk of worsened disability and relapse…
January 19, 2022 News by Marisa Wexler, MS Acthar Gel May Help RRMS Patients Who Fail Corticosteroids Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…
January 11, 2022 News by Marisa Wexler, MS High Levels of Gut Bacterial Toxins Found in Spinal Fluid of MS Patients People with multiple sclerosis (MS) have high levels of toxic compounds made by gut bacteria in the fluid around their brain and spinal cord, a study found. “This work not only furthers our understanding of the role of gut-brain communication in neurodegenerative disease progression, but also provides a potential…
December 14, 2021 News by Somi Igbene, PhD Regular Eye Screening Vital for MS Patients, Study Finds Visual disturbances are common in people with multiple sclerosis (MS), particularly among those with secondary progressive MS (SPMS), longer disease duration, and worse disability status, a new study has found. Yet, “visual complaints may occur in people with all types of MS, anytime along the disease course, and…
December 13, 2021 News by Marisa Wexler, MS Imaging of Retina Can Help in Monitoring Nerve Cell Damage in MS An imaging technique called optical coherence tomography (OCT) could be useful for monitoring nervous system damage in people with multiple sclerosis (MS), especially early on in the disease, a study in patients reports. The study, “Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study,”…
December 8, 2021 News by Marisa Wexler, MS Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of SpherixāsĀ RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…
December 7, 2021 News by Marisa Wexler, MS Worsening of Disability Evident in Older Patients Who Stop DMTs While older multiple sclerosis (MS) patients whose conditions are stable commonly stop using disease-modifying therapies (DMTs), a study indicates this decision can shortly lead toĀ a marked disease worsening in a substantial portion of them. “Our results raise important questions about the accepted practice of discontinuing medications once MS…
November 24, 2021 News by Marisa Wexler, MS 1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS Immunic TherapeuticsĀ has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…
November 17, 2021 News by Somi Igbene, PhD Long-term Supplement Use May Improve Gait, Strength in RRMS Long-term use of a high-dose nutritional supplement containing specific antioxidant vitamins and omega-3 and omega-6 fatty acids may boost walking performance and other measures of functional capacity in people with relapsing-remitting multiple sclerosis (RRMS), a new study found. The study, āThe Effects of Specific Omega-3 and…
November 17, 2021 News by Marisa Wexler, MS Vumerity Approved for RRMS in European Union The oral medication Vumerity (diroximel fumarate) has been approved by the European Commission to treat adults with relapsing-remitting multiple sclerosis (RRMS). “This approval is a significant step forward in improving treatment adherence for people living with relapsing MS, which can make a meaningful difference on treatment…
November 16, 2021 News by Patricia Inacio, PhD Cerebellar Lesions in RRMS Linked to Worsening Manual Dexterity The number of lesions affecting the cerebellum ā a brain region responsible for coordinating voluntary movements and motor skills such as balance, coordination, and posture ā predicts manual dexterity getting worse in people with relapsing-remitting multiple sclerosis (RRMS), according to a retrospective analysis. The study, āCerebellar pathology and…
November 16, 2021 News by Marta Figueiredo, PhD Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These clinical benefits, which entail no relapses or disease progression and no…